Compare ETS & NORD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETS | NORD |
|---|---|---|
| Founded | 2020 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Professional Services |
| Sector | Industrials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.4M | 95.5M |
| IPO Year | 2025 | 2005 |
| Metric | ETS | NORD |
|---|---|---|
| Price | $1.78 | $3.69 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 54.8K | N/A |
| Earning Date | 10-14-2026 | 07-25-2017 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.25 |
| EPS | N/A | N/A |
| Revenue | ★ $2,665,948.00 | $3,346.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.57 | N/A |
| 52 Week Low | $0.39 | N/A |
| 52 Week High | $2.75 | N/A |
| Indicator | ETS | NORD |
|---|---|---|
| Relative Strength Index (RSI) | 49.29 | N/A |
| Support Level | $0.56 | N/A |
| Resistance Level | $1.88 | N/A |
| Average True Range (ATR) | 0.37 | 0.00 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 44.83 | 0.00 |
Elite Express Holding Inc is a holding company that operates through its wholly owned subsidiary and specializes in last-mile delivery services within California. Its core business focuses on retrieving packages from distribution hubs and ensuring their prompt and secure delivery to recipients doorsteps. Committed to innovation and efficiency, its mission is to optimize last-mile logistics by providing efficient, reliable delivery solutions. The company mainly competes in the route delivery industry, which has several material barriers of entry, including: Substantial time and capital investment, Technological proficiency, Regulatory barriers, Balancing service quality and cost efficiency, and Effective Management.
Nordicus Partners Corp specializes in developing breakthrough therapeutics for diseases with unmet medical needs. The Company focuses on acquiring and developing drugs from biotech companies in the Nordics, a region known for its scientists, life sciences ecosystem, and drug discoveries and developments. Its current portfolio includes the preclinical biotechnology companies Orocidin A/S, Bio-Convert A/S, and NoviThera ApS. The Company is dedicated to developing breakthrough therapeutics in diseases with unmet medical needs, starting with oral disorders. It operates in the segment focused on developing medicines supporting oral health.